Brand Name
Dawnzera
Generic Name
Donidalorsen
View Brand Information FDA approval date: August 21, 2025
Form: Injection
What is Dawnzera (Donidalorsen)?
DAWNZERA™ is indicated for prophylaxis to prevent attacks of hereditary angioedema in adult and pediatric patients 12 years of age and older. DAWNZERA is a prekallikrein directed antisense oligonucleotide indicated for prophylaxis to prevent attacks of hereditary angioedema in adult and pediatric patients 12 years of age and older.
Approved To Treat
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
An Open-Label Study of Donidalorsen in Pediatric Patients Age 2 to Less Than 12 Years Old With Hereditary Angioedema
Summary: The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of donidalorsen in pediatric participants with hereditary angioedema (HAE) Type I (HAE-1) or Type II (HAE-2).